Triosephosphate isomerase deficiency

Triosephosphate isomerase deficiency
ICD-10	D55.2
ICD-9	282.3
OMIM	190450
DiseasesDB	30116

WikiDoc Resources for Triosephosphate isomerase deficiency
Articles
Most recent articles on Triosephosphate isomerase deficiency Most cited articles on Triosephosphate isomerase deficiency Review articles on Triosephosphate isomerase deficiency Articles on Triosephosphate isomerase deficiency in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Triosephosphate isomerase deficiency Images of Triosephosphate isomerase deficiency Photos of Triosephosphate isomerase deficiency Podcasts & MP3s on Triosephosphate isomerase deficiency Videos on Triosephosphate isomerase deficiency
Evidence Based Medicine
Cochrane Collaboration on Triosephosphate isomerase deficiency Bandolier on Triosephosphate isomerase deficiency TRIP on Triosephosphate isomerase deficiency
Clinical Trials
Ongoing Trials on Triosephosphate isomerase deficiency at Clinical Trials.gov Trial results on Triosephosphate isomerase deficiency Clinical Trials on Triosephosphate isomerase deficiency at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Triosephosphate isomerase deficiency NICE Guidance on Triosephosphate isomerase deficiency NHS PRODIGY Guidance FDA on Triosephosphate isomerase deficiency CDC on Triosephosphate isomerase deficiency
Books
Books on Triosephosphate isomerase deficiency
News
Triosephosphate isomerase deficiency in the news Be alerted to news on Triosephosphate isomerase deficiency News trends on Triosephosphate isomerase deficiency
Commentary
Blogs on Triosephosphate isomerase deficiency
Definitions
Definitions of Triosephosphate isomerase deficiency
Patient Resources / Community
Patient resources on Triosephosphate isomerase deficiency Discussion groups on Triosephosphate isomerase deficiency Patient Handouts on Triosephosphate isomerase deficiency Directions to Hospitals Treating Triosephosphate isomerase deficiency Risk calculators and risk factors for Triosephosphate isomerase deficiency
Healthcare Provider Resources
Symptoms of Triosephosphate isomerase deficiency Causes & Risk Factors for Triosephosphate isomerase deficiency Diagnostic studies for Triosephosphate isomerase deficiency Treatment of Triosephosphate isomerase deficiency
Continuing Medical Education (CME)
CME Programs on Triosephosphate isomerase deficiency
International
Triosephosphate isomerase deficiency en Espanol Triosephosphate isomerase deficiency en Francais
Business
Triosephosphate isomerase deficiency in the Marketplace Patents on Triosephosphate isomerase deficiency
Experimental / Informatics
List of terms related to Triosephosphate isomerase deficiency

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Triosephosphate isomerase deficiency is a rare, autosomal recessive disorder which was initially described in 1965. It is a unique glycolytic enzymopathy that is characterized by chronic haemolytic anaemia, cardiomyopathy, susceptibility to infections, severe neurological dysfunction, and, in most cases, death in early childhood. As mentioned, the disease is exceptionally rare with less than 100 patients diagnosed worldwide. In these patients, thirteen different mutations in the respective gene, which is located at chromosome 12p13 and encodes the ubiquitous housekeeping enzyme triosephosphate isomerase (TPI), have been discovered so far. TPI is a crucial enzyme of glycolysis and catalyzes the interconversion of dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. A marked decrease in TPI activity and an accumulation of dihydroxyacetone phosphate have been detected in erythrocyte extracts of homozygous (two identical mutant alleles) and compound heterozygous (two different mutant alleles) TPI deficiency patients. Remarkably, heterozygous individuals are clinically unaffected, even if their residual TPI activity is reduced. Recent work suggests that not a direct inactivation, but an alteration in TPI dimerization might underlie the pathology. This might explain why the disease is rare, but inactive TPI alleles have been detected at higher frequency implicating a heterozygote advantage of inactive TPI alleles.

Triosephosphate isomerase deficiency has an autosomal recessive pattern of inheritance.